EMA Authorised: Synjardy (empagliflozin;metformin) — Boehringer Ingelheim

View source ↗

Summary

The European Medicines Agency authorised Synjardy (empagliflozin/metformin) for the treatment of type 2 diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• SYNJARDY (empagliflozin and metformin hydrochloride)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2. MAH: Boehringer Ingelheim. Decision date: 18/11/2025